SPOTLIGHT: Developers end animal studies on toxicity

A combo act featuring a slate of top European companies and clinical research organizations are bringing a close to an 80-year era of animal tests for acute toxicity. New methods that don't depend on rodents are better and a lot less time consuming. That's a victory--the first big one--for the UK's National Centre for the Replacement, Refinement and Reduction of Animals in Research. Report

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.